I still holding AEZS also AF. I think this one is sure to make another run with all that they have coming down the pike. Plus notice how AEZS has bounced off the 20dma(currently at $2.78) a few times and I expect AEZS to start to rebound this week. Cheers!
AEZS has a decent sized pipeline to fall back on with numerous cancer indications. The key hope for this company is its Phase III Endometrial cancer trial that was granted a special protocol from the FDA in December. This news means if the trial data continues to be good, we could see the drug on the market before the completion of the Phase III trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AI
.PNG)
